Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directionsRiccardo Gerosa, Alberto Zambelli, Rita De Sanctis et al.|Critical Reviews in Oncology/Hematology|2024Cited by 87
Opportunities and Challenges of Synthetic Data Generation in OncologyFlavia Jacobs, Alberto Zambelli, Saverio D’Amico et al.|JCO Clinical Cancer Informatics|2023Cited by 36
Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic ResponsesJacopo Canzian, Alberto Zambelli, Fabio Conforti et al.|Cancers|2025Cited by 23
Clinical Review on the Management of Breast Cancer Visceral CrisisC. Benvenuti, Alberto Zambelli, Mariangela Gaudio et al.|Biomedicines|2023Cited by 17
Digital innovations in breast cancer care: exploring the potential and challenges of digital therapeutics and clinical decision support systemsFlavia Jacobs, Alberto Zambelli, Saverio D’Amico et al.|Digital Health|2024Cited by 14